RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and lowers the price target from $160 to $125.
RBC Capital Maintains Outperform on Moderna, Lowers Price Target to $125
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.